DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation1 article · 1 moderate

ICH Q8

Every DSRV article whose Regulatory Snapshot cites ICH Q8: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under ICH Q8?
1 DSRV article cite ICH Q8. Enforcement cases behind them: FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10. Inspection exposure across them: 1 moderate.
What does DSRV recommend for ICH Q8?
From the newest article (FDA's Evolving Stance on Real-Time Release Testing (RTRT)): RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 9 min readModerate exposurecited as a tag

    FDA's Evolving Stance on Real-Time Release Testing (RTRT)

    The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines.

    Case
    FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10.
    DSRV take
    RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under ICH Q8. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about ICH Q8

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.